Literature DB >> 6696992

Cytotoxicity of platelet activating factor and related alkyl-phospholipid analogs in human leukemia cells, polymorphonuclear neutrophils, and skin fibroblasts.

D R Hoffman, J Hajdu, F Snyder.   

Abstract

A series of 11 alkyl-phospholipid analogs, structurally related to platelet activating factor (L-PAF), were analyzed for cytotoxic activity in human leukemic (HL-60) cells, human polymorphonuclear neutrophils, and Detroit 551 human skin fibroblasts. The order of selectiveness of the analogs in their cytotoxic response toward HL-60 cells in comparison to neutrophils is 1-alkyl-2-acetamide-GPC greater than 1-alkyl-2-methoxy-GPC greater than D-PAF greater than 1-acyl-2-lyso-GPC greater than 1-alkyl-2-lyso-GPC greater than L-PAF. A time-sequenced progression of events caused by the most potent cytotoxic alkyl-phospholipid analogs was characterized by (a) a rapid decrease in the cellular uptake and incorporation of 3H-thymidine into DNA that was detectable 4 hr after exposure to the analog, (b) a release of lactate dehydrogenase activity into the media at 8 hr after exposure, and (c) a decrease in cell number due to cell death that begins at 12 hr after exposure. Treatment of HL-60 cells with 1-alkyl-2-methoxy-GPC for 1 hr destroyed 40% of the cells after a subsequent 24-hr incubation period. The varied biologic activities of L-PAF, including how it affects serotonin release from platelets, blood pressure in rats, and cytotoxic responses in normal and leukemic cells, are discussed in relation to its D-enantiomer, 3-alkyl-2-acetyl-GPC, and the 2-acetamide analog. This report characterizes the kinetic events of the cellular responses in both normal and HL-60 cells in relation to the antineoplastic activities of unnatural ether-linked phospholipid analogs that are structurally related to L-PAF.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6696992

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.

Authors:  G W Small; J C Strum; L W Daniel
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

2.  Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart.

Authors:  G Montrucchio; G Alloatti; F Mariano; R de Paulis; A Comino; G Emanuelli; G Camussi
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

3.  The effect of inhibitors of platelet aggregation on the metabolism of platelet-activating factor (PAF) in washed rabbit platelets.

Authors:  C O'Neill; A J Ammit; R Korth; S Fleming; X Wells
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

4.  Fc receptor triggering induces expression of surface activation antigens and release of platelet-activating factor in large granular lymphocytes.

Authors:  F Malavasi; C Tetta; A Funaro; G Bellone; E Ferrero; A C Franzone; P Dellabona; R Rusci; L Matera; G Camussi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

Review 5.  An update on the therapeutic role of alkylglycerols.

Authors:  Tommaso Iannitti; Beniamino Palmieri
Journal:  Mar Drugs       Date:  2010-08-05       Impact factor: 5.118

6.  The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity.

Authors:  Y Mandi; G Farkas; M Koltai; I Beladi; J M Mencia-Huerta; P Braquet
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

7.  The effect of culture medium composition on ether lipid cytotoxic activity.

Authors:  L Diomede; B Piovani; E J Modest; M Salmona
Journal:  Lipids       Date:  1993-03       Impact factor: 1.880

8.  Structure-function relationships of alkyl-lysophospholipid analogs in selective antitumor activity.

Authors:  W R Vogler; A C Olson; J Hajdu; M Shoji; R Raynor; J F Kuo
Journal:  Lipids       Date:  1993-06       Impact factor: 1.880

9.  Clonogenicity of normal and malignant hematopoietic progenitor cells after exposure to synthetic alkyl-lymphospholipids.

Authors:  I Dulisch; H A Neumann; G W Löhr; R Andreesen
Journal:  Blut       Date:  1985-12

10.  Antitumor activity of synthetic alkylphospholipids with or without PAF activity.

Authors:  I Kudo; S Nojima; H W Chang; R Yanoshita; H Hayashi; E Kondo; H Nomura; K Inoue
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.